CoraDoc review

The smallest monthly equivalent requires a year’s purchase

CoraDoc’s current linked offer lists $924 once for twelve months of semaglutide, equivalent to $77 per month, and $1,524 once for twelve months of tirzepatide, equivalent to $127. Those smaller equivalents are not flexible monthly payments. The financial decision is whether the full upfront purchase and its treatment term fit the patient’s circumstances.

The site also carries older six-month cards at $99 and $149 per month. Those describe different commitments rather than contradictory versions of a single monthly subscription. Compare the actual term and total attached to the selected offer, and obtain written confirmation of the quantity supplied and what happens after the paid period ends.

No subscription does not mean no commitment

CoraDoc’s language emphasizes one payment and no subscription. That can accurately describe a prepaid program while still leaving a purchaser committed for many months. Someone seeking the freedom to reassess the service after a single monthly payment should not infer that flexibility from the absence of automatic subscription billing.

The current maintenance advertising uses $129 and $229 monthly figures, but the complete obligation needs confirmation. Ask whether maintenance is available independently, what supply and care it includes and whether a minimum term applies. A renewal or maintenance offer should not be assumed to inherit the price or conditions of the initial twelve-month program.

The stated inclusions are useful, with a limited refund trigger

CoraDoc advertises a provider visit, supplies and two-day shipping without separate charges under its Triple Free Promise. Those inclusions are helpful when comparing a package with medication-only pricing elsewhere. Confirm that they apply to the selected current program, including the actual route for clinical follow-up during the paid term.

The advertised full refund concerns applicants who are not approved. It does not establish a general refund for unused months after a prescription is prepared or treatment begins. Ask when the payment becomes committed, how supplies are dispensed and what the agreement provides if the clinician changes or stops the prescription before the program ends.

Corporate identification is an important missing detail

CoraDoc publishes a Dallas address and telephone number, but its public legal material does not identify an operating LLC, corporation or professional entity. An address and a brand name are useful contact details; they do not establish which company takes responsibility for the consumer agreement or which medical practice provides treatment.

Ask for the seller’s legal name, treating practice and actual dispensing pharmacy before paying a year in advance. The missing operator identity also limits company-specific regulatory screening. A historical brand-name search is not the same as a check of an identified legal operator, and it should not be presented as a comprehensive assurance that no relevant regulatory history exists.

Treat certification and access badges as claims to confirm

CoraDoc displays all-50-state and LegitScript certification claims, along with a consultation-to-shipment estimate. These are seller claims rather than independently established guarantees for the patient’s selected prescription. Confirm state access, the assigned clinician and the specific pharmacy, and check the certification record rather than relying on the badge alone.

CoraDoc may interest someone comfortable with a defined prepaid program and clearly advertised inclusions. Its compounded-only menu does not establish an oral or approved-brand alternative, and the public content does not describe a distinct maternal-care pathway. The key tradeoff is the large upfront commitment against the low advertised equivalent. Resolve business identity, care access and interruption terms before deciding whether that commitment is appropriate.